Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…The Huntington’s Disease Structured Interview of Function (HD-SIF): A remotely administered caregiver interview for later stage HD
Objective: To create structured interviews for the UHDRS ’99 functional scales that can be remotely administered to caregivers of Huntington’s disease gene expansion carriers (HDGECs)…Lance-Adams Syndrome: A case series in El Salvador
Objective: To describe the clinical presentation and response to treatment of cases of Lance-Adams Syndrome in a Movement Disorders Clinic in El Salvador. Background: Lance-Adams…Visualising tau in patients with progressive supranuclear palsy using PI2620-PET
Objective: This study investigates the use of a new tau-specific PET radiotracer, [18F]-PI-2620, as a tool for visualising tau in the living brain. Background: The…Pallidal recordings in fully implanted dystonic patients: preliminary results
Objective: To describe oscillatory patterns of pallidal local field potentials (LFP) in fully implanted patients with dystonia. Background: New implantable devices for deep brain stimulation…How can patients’ trajectories inform the co-design of an integrated care network for people living with Parkinson’s Disease?
Objective: The aim of this study is to provide a better understanding of how patients’ experience could inform the design of an integrated care network…Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon
Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…Hyperkinetic Movement Disorders after Thalamic Lesions
Objective: To describe delayed hyperkinetic movement disorder after a thalamic lesion. Background: Lesions in the basal ganglia circuit can cause abnormal movement disorders. After thalamic…Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 132
- Next Page »